ATE477242T1 - Chinoline als allosterische enhancer von gaba-b- rezeptoren - Google Patents

Chinoline als allosterische enhancer von gaba-b- rezeptoren

Info

Publication number
ATE477242T1
ATE477242T1 AT05800636T AT05800636T ATE477242T1 AT E477242 T1 ATE477242 T1 AT E477242T1 AT 05800636 T AT05800636 T AT 05800636T AT 05800636 T AT05800636 T AT 05800636T AT E477242 T1 ATE477242 T1 AT E477242T1
Authority
AT
Austria
Prior art keywords
quinolines
gaba
receptors
allosteric enhancers
allosteric
Prior art date
Application number
AT05800636T
Other languages
English (en)
Inventor
Parichehr Malherbe
Raffaello Masciadri
Roger Norcross
Hasane Ratni
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE477242T1 publication Critical patent/ATE477242T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05800636T 2004-11-01 2005-10-25 Chinoline als allosterische enhancer von gaba-b- rezeptoren ATE477242T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105429 2004-11-01
PCT/EP2005/011403 WO2006048146A1 (en) 2004-11-01 2005-10-25 Quinoline as allosteric enhancers of the gaba-b receptors

Publications (1)

Publication Number Publication Date
ATE477242T1 true ATE477242T1 (de) 2010-08-15

Family

ID=35735244

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05800636T ATE477242T1 (de) 2004-11-01 2005-10-25 Chinoline als allosterische enhancer von gaba-b- rezeptoren

Country Status (16)

Country Link
US (1) US7576217B2 (de)
EP (1) EP1809605B1 (de)
JP (1) JP2008517963A (de)
KR (1) KR100876470B1 (de)
CN (1) CN101068788A (de)
AR (1) AR051612A1 (de)
AT (1) ATE477242T1 (de)
AU (1) AU2005300822B2 (de)
BR (1) BRPI0517929A (de)
CA (1) CA2586066A1 (de)
DE (1) DE602005022908D1 (de)
ES (1) ES2348246T3 (de)
MX (1) MX2007005112A (de)
RU (1) RU2378256C2 (de)
TW (1) TW200630341A (de)
WO (1) WO2006048146A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
NZ576036A (en) 2006-10-16 2010-10-29 Bionomics Ltd Naphthyridine containing compounds for treating anxiety disorders
WO2009041904A1 (en) * 2007-09-27 2009-04-02 Astrazeneca Ab Quinoline compounds having an activity against the gabab receptor
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
EP2707367B1 (de) 2011-05-12 2019-10-09 Bionomics Limited Verfahren zur herstellung von naphthyridinen
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB202414199D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel Compounds
GB202414200D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414192D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them
JPH0853419A (ja) * 1994-06-07 1996-02-27 Takeda Chem Ind Ltd キノリン誘導体およびそれらを含んでなる医薬
DE60018274T2 (de) * 1999-05-06 2005-08-04 Neurogen Corp., Branford Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
JP2002371078A (ja) * 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds
GB0226462D0 (en) * 2002-11-13 2002-12-18 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DE602005022908D1 (de) 2010-09-23
KR20070085594A (ko) 2007-08-27
AU2005300822B2 (en) 2010-12-02
ES2348246T3 (es) 2010-12-01
US7576217B2 (en) 2009-08-18
AU2005300822A1 (en) 2006-05-11
EP1809605B1 (de) 2010-08-11
BRPI0517929A (pt) 2008-10-21
US20060094754A1 (en) 2006-05-04
TW200630341A (en) 2006-09-01
AR051612A1 (es) 2007-01-24
KR100876470B1 (ko) 2008-12-31
CA2586066A1 (en) 2006-05-11
RU2378256C2 (ru) 2010-01-10
JP2008517963A (ja) 2008-05-29
EP1809605A1 (de) 2007-07-25
WO2006048146A1 (en) 2006-05-11
MX2007005112A (es) 2007-06-26
RU2007115639A (ru) 2008-12-10
CN101068788A (zh) 2007-11-07

Similar Documents

Publication Publication Date Title
DE60320529D1 (de) Chinolinderivate als npy antagonisten
IS8304A (is) Kínólín- og kínasólínafleiður með sækni í viðtaka af gerð 5HT1
DE602004027998D1 (de) Kondensierte n-heterozyclische verbindung und ihre verwendung als crf-rezeptor antagonist
DE602005016890D1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE498613T1 (de) Chinazolinonderivate als parp-hemmer
ATE486853T1 (de) Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
DE602005012267D1 (de) N von geräten
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DE602005012292D1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DK1802579T3 (da) Derivater af 3-arylaminopyridin
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
DE602005006744D1 (de) Chinolinderivate zur verwendung als inhibitoren von mycobakterien
ATE445600T1 (de) Derivate von tricyclischem lactam als 11-beta- hydroxysteroid-dehydrogenase-inhibitoren
ATE401893T1 (de) Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DE602006010870D1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
ATE412652T1 (de) Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
ATE477242T1 (de) Chinoline als allosterische enhancer von gaba-b- rezeptoren
DE602005002251D1 (de) Pyridazinonharnstoffe als antagonisten von a4-integrinen
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809605

Country of ref document: EP